Promotion of the Pauson-Khand Reaction using High Intensity Ultrasound

Autor: George G. Kirk, William J. Kerr, J. Gair Ford, David M. Lindsay, David Middlemiss

Publikováno v: Synlett. 2000:1415-1418

The use of a high powered ultrasound source in promoting the Pauson-Khand reaction has been extensively investigated. In conjunction with amines and N-oxide techniques, this developed methodology allows efficient access to a range of cyclopentenones

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da33bd112ecb7c073e3ce3dfac69e7ad
https://doi.org/10.1055/s-2000-7639

Mild and efficient preparation of alkynepentacarbonyldicobalt complexes containing the chiral (R) -(+) -Glyphos ligand

Autor: George G. Kirk, William J. Kerr, David Middlemiss

Publikováno v: Journal of Organometallic Chemistry. 519:93-101

A range of diastereomeric alkynepentacarbonyldicobalt complexes containing the (R)-(+)-Glyphos ligand have been prepared in moderate to good yields under standard thermal conditions. Additionally, novel tertiary amine N-oxide mediated reactions have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eb38e8cab7f6d5cc7045c4a6862d9bb4
https://doi.org/10.1016/s0022-328x(96)06174-8

ChemInform Abstract: Enantioselective Pauson-Khand Reactions Mediated by a Chiral Amine N- Oxide

Autor: William J. Kerr, George G. Kirk, David Middlemiss

Publikováno v: ChemInform. 27

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6d67eedea90b9dbc36f688a521d021a0
https://doi.org/10.1002/chin.199611127

ChemInform Abstract: Promotion of the Pauson-Khand Reaction Using High Intensity Ultrasound

Autor: George G. Kirk, J. Gair Ford, David M. Lindsay, William J. Kerr, David Middlemiss

Publikováno v: ChemInform. 32

The use of a high powered ultrasound source in promoting the Pauson-Khand reaction has been extensively investigated. In conjunction with amines and N-oxide techniques, this developed methodology allows efficient access to a range of cyclopentenones

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7f28568afdee784a7761a407bc9d413b
https://doi.org/10.1002/chin.200105069

Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases.

Autor: Dhaenens BAE; Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.; ENCORE Expertise Centre for Neurodevelopmental Disorders, Erasmus MC, Rotterdam, The Netherlands., Heimann G; Biostatistics & Pharmacometrics, Novartis Pharma AG, Basel, Switzerland., Bakker A; Children's Tumor Foundation, New York, New York, USA., Nievo M; Children's Tumor Foundation, New York, New York, USA., Ferner RE; Neurofibromatosis Service, Department of Neurology, Guy's and St. Thomas' NHS Foundation Trust London, Great Maze Pond, London, UK., Evans DG; Centre for Genomic Medicine, Division of Evolution, Infection and Genomic Sciences, University of Manchester, St Mary's Hospital, Manchester, UK., Wolkenstein P; Department of Dermatology, Henri-Mondor Hospital, Créteil, France., Leubner J; Department of Pediatric Neurology, Charité Universitätsmedizin Berlin-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Potratz C; Department of Pediatric Neurology, Charité Universitätsmedizin Berlin-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Carton C; Department of Human Genetics, KU Leuven, Leuven, Belgium., Iloeje U; Medical Affairs, SpringWorks Therapeutics, Stamford, Connecticut, USA., Kirk G; AstraZeneca Oncology R&D, Cambridge, UK., Blakeley JO; Department of Neurology, Neuro-Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Plotkin S; Cancer Center and Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA., Fisher MJ; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA., Kim A; Division of Oncology, Children's National Hospital, Washington DC, District of Columbia, USA., Driever PH; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Azizi AA; Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Wien, Austria., Widemann BC; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Gross A; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Parke T; Berry Consultants, Abingdon, UK., Legius E; Department of Human Genetics, KU Leuven, Leuven, Belgium.; Department of Clinical Genetics, UZ Leuven, Leuven, Belgium.; Full Member of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Nijmegen, The Netherlands (E.L., R.O.)., Oostenbrink R; Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.; ENCORE Expertise Centre for Neurodevelopmental Disorders, Erasmus MC, Rotterdam, The Netherlands.; Full Member of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Nijmegen, The Netherlands.

Publikováno v: Neuro-oncology practice [Neurooncol Pract] 2024 Jan 04; Vol. 11 (4), pp. 395-403. Date of Electronic Publication: 2024 Jan 04 (Print Publication: 2024).